TMDX

TransMedics Group, Inc.

Fundamental data last updated:October 24, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

 


Analyze TMDX on TradingView

VALUATION

P/E

13.57

Market Cap ($M USD)

$2.34B

Forward P/E

9.56

PEG

0.23

PRICE TO SALES

3.69

PRICE TO BOOK

4.72

EV / EBITDA

19.66

5-Year Average P/E

Free Cash Flow Yield

6.46%

DCF Value

$-1169.90

Graham Number

$40.20

Price to FCF

15.49

EV to FCF

17.85

Earnings Yield

7.37%

FCF Yield

6.46%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$5.00

Next Year EPS Growth Estimate

$7.10

Next Year Revenue Growth Estimate

$1.22B

Return on Equity (ROE)

41.92%

FREE CASH FLOW

Operating Margin

14.85%

Debt-to-Equity

0.99

Piotroski F-Score

4

Altman Z-Score

2.40

Return on Invested Capital (ROIC)

7.03%

Current Ratio

6.74

Quick Ratio

6.19

Net Debt to EBITDA

2.60

Interest Coverage

5.40

Gross Profit margin

59.09%

FCF PER SHARE

$4.40

REVENUE PER SHARE

$18.49

Analyze TMDX on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing TransMedics Group, Inc. significantly. With a DCF value deeply negative and a Graham Number far below the snapshot price, there’s a glaring disconnect. The Forward P/E of 9.55 suggests undervaluation relative to future earnings, while an Earnings Yield of 7.38% indicates decent returns. However, the Altman Z-score of 2.36 raises caution about financial stability, hinting at moderate distress. This stock is a complex puzzle of potential growth and underlying risk.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, TransMedics is well-positioned to leverage AI for enhancing operational efficiencies and product innovation. The healthcare sector's ongoing digital transformation offers fertile ground for integrating advanced technologies. This adaptability could bolster their competitive edge in a rapidly evolving market.

The Bull Case

For the value-driven investor, TransMedics offers compelling reasons to buy. A robust ROIC of 7.03% and a healthy FCF Yield of 6.46% underscore its capital efficiency. Despite a middling Piotroski F-Score of 4, the company boasts strong margins, with an Operating Margin of 14.85% and a Gross Profit Margin of 59.09%. These metrics suggest solid pricing power and effective cost management, making it an attractive proposition for those seeking growth at a reasonable price.

The Bear Case

Yet, the stock is not without its pitfalls. The Price/Book ratio of 4.72 and Price/Sales of 3.68 indicate a potentially overvalued position. With a snapshot price extended above its 50-Day and 200-Day SMAs, technical overextension is evident. The Net Debt to EBITDA ratio of 2.60 and an Interest Coverage of 5.40 highlight financial leverage concerns. These factors, combined with a modest Piotroski F-Score, suggest caution is warranted.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$122.67

Institutional Ownership %

1-Year Beta

2.06

Insider Buying % (6 Mo)

Distance to 52-Week High

129.99%

Distance to 52-Week Low

11.39%

EARNINGS SURPRISE %

-51.61%

50-DAY SMA

$94.39

200-DAY SMA

$118.73

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.